
Katalognummer: 10333 - RLDG0119DIGLOCK
Produktkategori: Företag och industri > Vetenskap och laboratorium
Storlek: EACH
EL-1611-011
Adalimumab (Trade name Humira®) is a human monoclonal antibody used to block the action of tumor necrosis factor alpha (TNF- ). TNF-α is a strong proinflammatory cytokine involved in normal immunity and also various autoimmune diseases. The Adalimumab ELISA kit is designed to measure free Adalimumab with high specificity and sensitivity. The assay design uses a pair of antibodies allowing detection of whole Adalimumab molecules in biological matrices The Adalimumab ELISA kit is designed to measure free Adalimumab with high specificity and sensitivity. This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Adalimumab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Adalimumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Adaliumumab present in test samples and the concentration is calculated from the standard series.
EL-1611-031
Cetuximab (Erbitux®) is a chimeric IgG1 monoclonal antibody that binds the extra-cellular domain of the epidermal growth factor receptor (EGFR). It is a 152-kDa molecule composed of four polypeptide chains: two identical heavy chains and two identical light chains, consisting of 449 and 214 amino acids, respectively, bound by covalent and non-covalent bonds. The bond with EGFR is characterized by a higher affinity than either endogenous ligand, as epidermal growth factor (EGF), or transforming growth factor alpha. This binding inhibits activation of the receptor tyrosine kinase and the associated downstream signaling that includes the mitogenactivated protein kinase, phosphoinositide 3-kinase/ Akt and the Janus kinases/ signal transducers and activator of transcription (Stat) pathways. Furthermore Cetuximab induces antibody-mediated receptor dimerization, internalization and degradation leading to receptor down-regulation. In addition, it exhibits antibody-dependent cellular cytotoxicity that could contribute to its antitumor effect. The Cetuximab ELISA kit is designed to measure free Cetuximab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Cetuximab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Cetuximab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Cetuximab present in test samples and the concentration is calculated from the standard series.
EL-1611-051
Etanercept (trade name Enbrel®) is a protein drug used to treat autoimmune diseases by adsorbing tumor necrosis factor (TNF; a soluble inflammatory cytokine). Etanercept is a fusion protein produced through expression of recombinant DNA by linking the extracellular ligand-binding portion of TNFRSF1B to the Fc component of human immunoglobulin G1 (IgG1). It reduces the effect of naturally present TNF, functioning as a decoy receptor that binds to TNF. Etanercept is indicated for the treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and moderately to severely active polyarticular juvenile idiopathic arthritis. Serum concentration of Enbrel® may predict some clinical outcome during maintenance therapy. The Etanercept ELISA kit is designed to measure free Etanercept with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Etanercept 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Etanercept present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Etanercept present in test samples and the concentration is calculated from the standard series.

By: Author , 2 Comment
23 August 2025

By: Author , 2 Comment
16 August 2025

By: Author , 2 Comment
1 August 2025

By: Author , 2 Comment
22 July 2025

